Bethany Sensenig
Director/Board Member at SUPERNUS PHARMACEUTICALS, INC.
Net worth: - $ as of 31/03/2024
Profile
Bethany L.
Sensenig is an Independent Director at Supernus Pharmaceuticals, Inc. and the Chief Executive & Financial Officer at Naia Rare Diseases LLC.
She previously worked as the Vice President-Finance & Commercial Operations at Biogen, Inc. from 2006 to 2019.
Additionally, she served as the Chief Financial Officer & Head-US Operations at Minovia Therapeutics Ltd.
from 2019 to 2022.
In 2023, she briefly held the position of Chief Executive & Financial Officer at 9 Meters Biopharma, Inc. Ms. Sensenig completed her undergraduate degree at Montreat College and holds an MBA from Western Carolina University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
9 METERS BIOPHARMA, INC.
0.17% | 24/04/2023 | 25,089 ( 0.17% ) | - $ | 31/03/2024 |
Bethany Sensenig active positions
| Companies | Position | Start |
|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. | Director/Board Member | 21/08/2023 |
Naia Rare Diseases LLC
 Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Chief Executive Officer | - |
Former positions of Bethany Sensenig
| Companies | Position | End |
|---|---|---|
| 9 METERS BIOPHARMA, INC. | Chief Executive Officer | 17/07/2023 |
Minovia Therapeutics Ltd.
 Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Director of Finance/CFO | 01/01/2022 |
| BIOGEN INC. | Corporate Officer/Principal | 01/03/2019 |
Training of Bethany Sensenig
| Montreat College | Undergraduate Degree |
| Western Carolina University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| SUPERNUS PHARMACEUTICALS, INC. | Health Technology |
| 9 METERS BIOPHARMA, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Health Technology |
Naia Rare Diseases LLC
Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Health Services |
- Stock Market
- Insiders
- Bethany Sensenig